Goodwin advised Balderton Capital on its investment. TreasurySpring has raised £23 million in Series B funding led by Balderton Capital. Mubadala Capital also participated in the round,...
You must be a Standard 1 Year member to access this content.
Bird & Bird advised Lonza, while Goodwin and NautaDutilh advised Synaffix. SynAffix B.V. announced the sale to Lonza Group AG. Under the terms of the sale and...
You must be a Standard 1 Year member to access this content.
Goodwin advised Material Impact and Dr. Martens on the deal. Material Impact and Dr. Martens announced their investment as part of an $18 million funding round for...
You must be a Standard 1 Year member to access this content.
Goodwin advised OKRA.ai on the deal. Bird & Bird and Ropes & Gray advised Envision Pharma Group. OKRA.ai announced their acquisition by Envision Pharma Group (Envision). Envision...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Ducentis BioTherapeutics on the deal. Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of...
You must be a Standard 1 Year member to access this content.
Goodwin advised Syndesi Therapeutics on the deal. Deloitte Legal assisted the selling shareholders and the company with the sale of Syndesi Therapeutics. Syndesi annouunced its acquisition by...
You must be a Standard 1 Year member to access this content.
Goodwin advised BIVF, Novo and Evotec on the deal. Boehringer Ingelheim Venture Fund GmbH (“BIVF”), Novo Holdings REPAIR Impact Fund (“Novo”) and Evotec SE (“Evotec”) led...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Omega Funds on the deal. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small...
You must be a Standard 1 Year member to access this content.
